Lone Dybdal Nilsson

Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark.

EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark.

Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark.

OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark.

IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark.

Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020.

Cobis A/S provides business support services.

Symbion A/S provides office communities, meeting facilities, conference facilities, business development and capital for start-up companies. The company was founded in 1986 and is headquartered in Copenhagen, Denmark.

Dandrit Biotech A/S conducts clinical research, trading, and manufacturing for the pharmaceutical industry. It focuses on research and development of medicines. The company was founded on April 1, 2001 and is headquartered in Hørsholm, Denmark.

Part of Ejendomsselskabet Hvidovre Torv Holding AS, Ejendomsselskabet Hvidovre Torv AS engages in rental of commercial real estate properties. The company is based in Aarhus, Denmark.

Advanced MR Analytics AB offers solutions for body composition analysis. It transforms subjective magnetic resonance images into fat and muscle measurements. The firm provides technical research such as data acquisition and reconstruction; registration and fusion; machine learning and signal representation; modelling and simulation; simulation, classification, and quantification; visualization and image enhancement; and user interfaces and interaction. The company was founded by David Magnus Borga and Olof Erik Gunnar Dahlqvist Leinhard in 2010 and is headquartered in Link?ping, Sweden.

Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland.

NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands.

Phillips-Medisize A/S designs, develops, and manufactures injection, inhalation, and connectivity devices. It co-markets intelligent patient compliance device solutions that enable patients to manage their drug treatment regimes. The firm offers pressurized metered dose inhalers, such as Asmair for asthma and chronic obstructive pulmonary diseases; and Insulair, for use with liquid drug formulations for pulmonary drug delivery in patients with diabetes; and tablet reminders. The company's injection technology accelerators are focuses on modules and concept solutions for: disposable and reusable concepts, mechanical and electronic motor systems, dosing controls, needle protection systems, low and high volume concepts, data collection and memory systems, and wireless data transfer systems. Medicom Innovation Partner was founded in 1989 and is headquartered in Struer, Denmark.

Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA.

Hempel Fonden provides and maintains a solid economic base for the company. It also provides assistance for cultural, social, humanitarian, scientific, and artistic purposes, with a special focus on education for children in need and research in environmentally sustainable technologies in the coating industry. The company was founded in 1964 and is headquartered in Copenhagen, Denmark.

Beta Bionics, Inc. operates a medical technology company leveraging lifelong, machine-learning, artificial intelligence to develop and commercialize the autonomous bionic pancreas. The company was founded by Edward R. Damiano in October 21, 2015 and is headquartered in Boston, MA.

Rigshospitalet is a highly specialized hospital in Denmark that ensures all patients in Denmark have a treatment offer, no matter how rare or complicated their illness is. The hospital is located on Blegdamsvej and in Glostrup. Rigshospitalet prioritizes research and achieves and disseminates results through extensive national and international cooperation. The hospital has subsidiaries in Denmark.

Part of Hempel Fonden, Hempel Invest A/S is a Danish company that works dedicatedly to make a difference. The company is based in Copenhagen, Denmark. The company gives children around the world the opportunity to learn, make coating more efficient and sustainable, preserve nature's diversity, and support good initiatives that have the potential to make a big difference. Founded in 2009, Hempel Invest is supported by the Hempel Foundation, which actively works to make a difference by funding projects within their focus areas.

Part of Agilent Technologies, Inc., Dako ApS is a Danish company that designs and manufactures cancer diagnostic systems. The company is based in Glostrup, Denmark.

Atos Medical AB engages in the development and manufacture of medical products for the ear, nose, and throat areas. The firm provides solutions to people who breathe through a stoma. It offers a range of voice- and pulmonary rehabilitation devices, and provox products. The company was founded by Gert Persson and Jan-Ove Persson in 1986 and is headquartered in Malmo, Sweden.

Part of Bioporto A/S, Bioporto Diagnostics A/S is a Danish company that engages in research and experimental development on biotechnology. The company is based in Gentofte, Denmark. Peter Morch Eriksen has been the CEO of the company since 2013.

Orana A/S supplies fruit based raw materials for dairy, beverages and food service. Its products include dairy products, beverages, bakery products and desserts/toppings. The company is headquartered in Rynkeby, Denmark.

Dako Denmark A/S designs and manufactures cancer diagnostic systems. It produces reagents, antibodies, instruments, and software solutions to make diagnoses and determine treatments for patients suffering from cancer. The firm's product areas encompass Immunohistochemistry, pharmacoDiagnostics, molecular pathology, Hematoxylin and Eosin stain, special stains, flow Cytometry, and specific proteins. The company was founded by Niels Harboe in 1966 and is headquartered in Glostrup, Denmark.

Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France.

Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark.